Clostridium difficile infection (CDI) attacks the gut resulting in diarrhoea and inflammation of the colon.
It is classified as the number one antibiotic-resistant bacterial threat in the USA where there are 500,000 cases of CDI and 30,000 deaths.
CDI is an increasing problem for hospitalized patients in the US, the EU and Australia.
Our recent NHMRC funded project established drug leads against CDI and we now require continued studies to develop our drug leads towards marketable therapeutics.
National Health and Medical Research Council
2017 – 2019
University of Wollongong